<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-15.8'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//www.biotechreality.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://www.biotechreality.com/2026/08/biomarin-alesta-therapeutics-acquisition.html</loc>
  <lastmod>2026-08-18T19:49:18Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>BioMarin Alesta Therapeutics Acquisition: BioMarin Acquires Alesta to Secure Oral HPP Candidate ALE1 for $275M Upfront</news:title>
   <news:publication_date>2026-08-18T19:49:14Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/08/aastrazeneca-discontinues-volrustomig.html</loc>
  <lastmod>2026-08-18T18:46:04Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>AstraZeneca Discontinues Volrustomig Phase III Trial in First-Line Metastatic Non-Small Cell Lung Cancer</news:title>
   <news:publication_date>2026-08-18T18:45:26Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/08/pfizer-valneva-lyme-disease-vaccine-ema-validation.html</loc>
  <lastmod>2026-08-16T18:42:07Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Pfizer Valneva Lyme Disease Vaccine Candidate Clears EMA Application Review Milestone</news:title>
   <news:publication_date>2026-08-16T18:42:03Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
